European scientists are on teh cusp of launching human trials for a potentially groundbreaking gene therapy aimed at simplifying the treatment of obesity. The novel approach, reported by the swiss newspaper “Neue Zürcher Zeitung,” seeks to replace frequent weight-loss injections with a single annual dose by instructing the body to naturally produce appetite-suppressing hormones. While promising a less burdensome regimen for patients, the therapy also presents notable risks that researchers are carefully evaluating before wider implementation.
Foto. pexels.com/Karolina Kaboompics
European scientists are preparing to launch initial trials of a novel gene therapy that could potentially replace annual courses of weight-loss injections with a single yearly dose. The development offers a potentially less burdensome approach to managing obesity, a growing global health concern.
Kokteilis
Lielais horoskops februārim visām zodiaka zīmēm: kāds iemīlēsies, bet kādu citu gaida papildu ienākumi
Viņš to nekad neatzīs: žurnālists nācis uz pēdām Putina mazajam noslēpumam, kas daudz ko izskaidro
Epstīna dokumentos parādās viens vārds pēc otra: tūkstošiem reižu minēts Putins, atkāpjas Slovākijas premjera padomnieks
Lasīt citas ziņas
According to a report in the Swiss newspaper “Neue Zürcher Zeitung,” researchers are developing a new gene therapy that could fundamentally change how obesity is treated. Instead of administering hormones directly, the therapy introduces a gene that instructs the body to produce GLP-1, a substance that suppresses appetite and promotes weight loss.
Initial human clinical trials in Europe are anticipated to begin later this year.
Current medications work by directly administering hormones via regular injections, reducing feelings of hunger and leading to weight loss. However, these effects are temporary, and side effects are often observed.
The new technology takes a different approach: copies of the GLP-1 gene are delivered to the body, prompting cells to produce the hormone themselves. This effect could last for several months, or even a year, requiring only a single injection.
Studies conducted on animals showed that mice lost up to 20% of their body weight over three weeks, and even when consuming a high-calorie diet, they showed limited weight gain.
Despite the promising results, medical professionals are approaching this technology with caution. Key risks include:
- the inability to “switch off” the gene if adverse effects occur;
- the potential for inflammation in organs;
- six deaths during other gene therapy treatments last year;
- unpredictable long-term consequences.
Existing medications can be discontinued if necessary, but gene therapy is irreversible. If the body reacts negatively, halting the process will not be possible. Even the developers acknowledge that no one knows how long the gene will remain active or how the body will respond after several years.
Some doctors point out that obesity is not a life-threatening genetic disease justifying such a risky therapy.
Trials have not yet begun, and the therapy’s safety remains unproven. Estimates suggest that the cost of a single injection could reach hundreds of thousands, or even millions, of dollars in the future.
Experts emphasize that this does not appear to be a “magic bullet,” but rather a very expensive and potentially dangerous procedure.
Tēmas
FB.init({ appId: '', cookie: false, xfbml: true, version: 'v3.1' });
FB.AppEvents.logPageView();
FacebookIsReady = true; if (typeof FacebookIsReadyCallback != 'undefined') { FacebookIsReadyCallback(); } };
(function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js#xfbml=1&version=v3.2"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
